Peginterferon alfa-2b clinical trials
Also written PegIntron, PEG-interferon alfa-2b, SCH 054031 and SCH 54031.
How each study uses peginterferon alfa-2b is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the peginterferon alfa-2b studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Jan 2001 · PEGINTRON · BLA 103949 (FDA, Drugs@FDA)
- European Union
- 24 May 2000 · PegIntron · EMEA/H/C/000280 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Studies by the year they started
135 studies that test it; most in 2006 (11)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 1998 | 2 |
| 2000 | 5 |
| 2001 | 4 |
| 2002 | 10 |
| 2003 | 6 |
| 2004 | 5 |
| 2005 | 10 |
| 2006 | 11 |
| 2007 | 10 |
| 2008 | 8 |
| 2009 | 3 |
| 2011 | 7 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 11 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 55 · Other 84
Merck Sharp & Dohme LLC (43) · M.D. Anderson Cancer Center (6) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Tanabe Pharma Corporation (3) · National Cancer Institute (NCI) (3) · Xiamen Amoytop Biotech Co., Ltd. (2) · The Wistar Institute (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
Often tested with
Tested in the same studies.
Ribavirin (41) · Boceprevir (5) · Telaprevir (4) · Imatinib (3) · Pembrolizumab (3) · Nilotinib (2) · Rituximab (2) · Temozolomide (2)
Related medicines
As reviewed, each with the page that says it.
- One of Interferons source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6
Studies that test peginterferon alfa-2b.
- Nov 2026Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in AdultsNot applicable · Beijing Ditan Hospital
- Nov 2026Efficacy and Safety of Peginterferon in ET and PV.Not applicable · Zhenya Hong
- Dec 2026Peginterferon Treatment Study for Inactive Chronic Hepatitis B PatientsPhase 4 · Third Affiliated Hospital, Sun Yat-Sen University
- Mar 2027A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV CirrhosisNot applicable · Xiamen Humanity Hospital
- Oct 2027Interferon-α Maintenance in Favorable-Risk AMLPhase 2 · Peking University People's Hospital
- Oct 2027Clinical Trial of Pegylated Interferon α-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .Not applicable · Zhengzhou Children's Hospital, China
Studies
Open first, then newest update. How each study uses peginterferon alfa-2b is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 139
- Interferon-α Maintenance in Favorable-Risk AMLRecruitingPhase 2Peking University People's HospitalNCT07925554Written as pegylated interferon alfa-2b
- Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionNot yet recruitingEarly Phase 1Ningbo No.2 HospitalNCT07553767Written as Peginterferon alfa-2b
- Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis BNot yet recruitingPhase 4Nanfang Hospital, Southern Medical UniversityNCT07231276Written as Peginterferon alfa-2b Injection
- Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETRecruitingPhase 2Xiamen Amoytop Biotech Co., Ltd.NCT06552429Written as Peginterferon α-2b injection
- A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV CirrhosisNot yet recruitingNot applicableXiamen Humanity HospitalNCT07183293Written as Peginterferon alfa-2b combined with NAs
- Clinical Trial of Pegylated Interferon α-2b Via Nebulization for Treatment of Hand, Foot, and Mouth Disease .RecruitingNot applicableZhengzhou Children's Hospital, ChinaNCT07008755Written as Peginterferon α-2b injection
- Peginterferon Treatment Study for Inactive Chronic Hepatitis B PatientsRecruitingPhase 4Third Affiliated Hospital, Sun Yat-Sen UniversityNCT05182463Written as Peginterferon Alfa-2B
- Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAgNot yet recruitingPhase 4Huashan HospitalNCT06900166Written as PegIFN alfa-2b
- Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus PneumoniaRecruitingNot applicableWest China Second University HospitalNCT06881056Written as Peginterferon α-2b injection
- Peginterferon α-2b Injection for the Treatment of Pediatric RSV BronchiolitisRecruitingNot applicableChildren's Hospital of Soochow UniversityNCT06827249Written as Peginterferon α-2b injection
- Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in AdultsEnrolling by invitationNot applicableBeijing Ditan HospitalNCT06777173Written as Peg interferon alfa-2b
- Efficacy and Safety of Peginterferon in ET and PV.RecruitingNot applicableZhenya HongNCT06734637Written as Peginterferon α-2b injection
- Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential ThrombocythemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT04226950Written as Pegylated interferon alfa-2b
- Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential ThrombocythemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05395507Written as Pegylated interferon alfa-2b
- Peginterferon α-2b Combined CO2 Laser in Condylomata AcuminataNot yet recruitingNot applicableZhangyu BuNCT06430190Written as Peginterferon α-2b injection
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01466192Written as Peginterferon alfa-2b
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis CCompletedPhase 1Tanabe Pharma CorporationNCT00630058Written as MP-424(H), PEG-IFN-a-2b, RBV
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected PatientsCompletedPhase 3Tanabe Pharma CorporationNCT01468584Written as Peginterferon alfa-2b
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedPhase 2Australasian Leukaemia and Lymphoma GroupNCT02001818Written as Nilotinib, Pegylated interferon alpha-2b, Imatinib
- A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis BCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT04846491Written as Peginterferon alfa-2b injection
See all 139 studies that test peginterferon alfa-2b →
Given beside what is tested · 51 — peginterferon alfa-2b is usual care or a partner of the new treatment
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05870475Written as Pegylated interferon α-2b
- Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk MelanomaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT00539591Written as Peginterferon alfa-2b
- Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe FibrosisCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT00148837Written as Peg-interferon alpha 2b + Ribavirin(drug)
- Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT01463956Written as Peg-Interferon α-2b or Peg-Interferon α-2a
- Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT02948426Written as Autologous Monocytes + ACTIMMUNE + SYLATRON
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00781274Written as Peginterferon Alfa-2b
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT00780416Written as Peginterferon Alfa-2b
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyCompletedPhase 3Tanabe Pharma CorporationNCT00780910Written as Peginterferon Alfa-2b
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedPhase 3Anna CrucetaNCT01718301Written as Peginterferon alfa-2b
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01353911Written as Peg-interferon alfa-2b
- Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)TerminatedPhase 2Merck Sharp & Dohme LLCNCT01440595Written as Peginterferon alfa-2b (Peg-IFN)
- Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)Status unknownPhase 1Luis MontanerNCT03588715Written as Pegylated Interferon alpha 2b (peg-IFN-α2b)
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)CompletedPhase 3Merck Sharp & Dohme LLCNCT01023035Written as Peginterferon alfa-2b (PEG2b)
- Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)CompletedPhase 3Merck Sharp & Dohme LLCNCT00910624Written as Peginterferon alfa-2b (SCH 54031)
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)CompletedPhase 3Merck Sharp & Dohme LLCNCT01425203Written as peginterferon alfa-2b
- A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)CompletedPhase 2Merck Sharp & Dohme LLCNCT01710501Written as pegylated interferon alfa-2b
- Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma PatientsCompletedPhase 2M.D. Anderson Cancer CenterNCT00525031Written as Pegylated Interferon Alpha-2b (PGI)
- Peginterferon and TIL Therapy for Metastatic MelanomaCompletedPhase 1/2Inge Marie SvaneNCT02379195Written as Peginterferon alfa-2b
- Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver FibrosisStatus unknownNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT03920605Written as Peginterferon Alfa-2b
- Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver FibrosisStatus unknownNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT03919565Written as Peginterferon Alfa-2b
Showing 20 of 51.
As the comparator · 11 — what is tested is compared with peginterferon alfa-2b
- Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionCompletedPhase 3PharmaEssentiaNCT04382937Written as PEG-Intron + Ribavirin
- Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis CCompletedPhase 2Medtronic Corporate Technologies and New VenturesNCT00919633Written as peginterferon alfa-2b
- An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected PatientsCompletedPhase 3BiocadNCT02103439Written as PegIntron
- Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).CompletedPhase 4Hoffmann-La RocheNCT00087607Written as Peginterferon alfa-2b (PEG-Intron)
- The SIM-SOF Trial for Hepatitis CCompletedPhase 4Center For Hepatitis C, Atlanta, GANCT02168361Written as Pegylated Interferon alfa-2b
- Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT02204475Written as PegIntron
- Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis CCompletedPhase 2/3BiocadNCT01740089Written as PegIntron
- NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) PatientsStatus unknownPhase 3Clinical Research Organization, Dhaka, BangladeshNCT01374308Written as Pegylated interferon alpha 2b
- Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHCCompletedPhase 4Brooke Army Medical CenterNCT00207363Written as Ribavirin, Peg interferon alfa 2b
- Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis CCompletedPhase 1/2Biolex Therapeutics, Inc.NCT00593151Written as pegylated IFNa2b
- Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCVCompletedPhase 2Biolex Therapeutics, Inc.NCT00863239Written as PEG-Intron™
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Interferon-α Maintenance in Favorable-Risk AMLNov 9, 2026NCT07925554
Codes
What other systems call peginterferon alfa-2b · ClinicalTrials.gg INT004289
- MeSH (NLM) C417083peginterferon alfa-2bConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G8RGG88B68PEGINTERFERON ALFA-2BConfirmed FDA, NLM, Wikidata
- RxNorm 253453Confirmed FDA, Wikidata
- Wikidata Q7160789peginterferon alfa-2bConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1845Peginterferon Alfa-2bOne source FDA
- DrugBank DB00022One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C417083 | peginterferon alfa-2b | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G8RGG88B68 | PEGINTERFERON ALFA-2B | Confirmed FDA, NLM, Wikidata |
| RxNorm | 253453 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7160789 | peginterferon alfa-2b | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1845 | Peginterferon Alfa-2b | One source FDA |
| DrugBank | DB00022 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.